dimethyl-(1,1,2,2-tetramethyl-propyl)-amine | 3733-36-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: dimethyl-(1,1,2,2-tetramethyl-propyl)-amine
• 英文别名: Dimethyl-(1,1,2,2-tetramethyl-propyl)-amin；2-Dimethylamino-2,3,3-trimethyl-butan；1-Dimethylamino-1,1,2,2-tetramethyl-propan；2-Methyl-3,3-dimethyl-dimethylamino-butan；2,3,3-Trimethyl-dimethylamino-butan；N,N,1,1,2,2-Hexamethylpropylamin；Hexamethylpropyleamine；N,N,2,3,3-pentamethylbutan-2-amine
• CAS: 3733-36-6
• 化学式: C₉H₂₁N
• 分子量: 143.272
• InChiKey: DDXWCWBJFFJKGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2921199090

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 2,3,3-三甲基丁烷-2-胺 在 甲酸 作用下， 生成 dimethyl-(1,1,2,2-tetramethyl-propyl)-amine
  参考文献：
  名称：

  Substituierte t-Hexylamine als neuer Typ hypotensiv wirksamer Verbindungen

  摘要：

  DOI：

  10.1007/bf02158110

文献信息

• HEPATITIS C VIRUS INHIBITORS
  申请人：McKinnell Robert Murray

  公开号：US20130287731A1

  公开（公告）日：2013-10-31

  The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

  这项发明提供了以下式(I)或(II)的化合物： 其中变量在规范中定义，或其药用盐，这些化合物是乙型肝炎病毒复制的抑制剂。该发明还提供了包括这些化合物的药物组合物，使用这些化合物治疗乙型肝炎病毒感染的方法，以及用于制备这些化合物的工艺和中间体。
• INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME
  申请人：Sircar Jagadish

  公开号：US20070238736A9

  公开（公告）日：2007-10-11

  Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 3 , R 4 , X, and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了抑制MIF的抑制剂，其在治疗多种疾病方面具有用途，包括治疗与MIF活性相关的病理条件。 MIF的抑制剂具有以下结构：包括立体异构体，前药和其药学上可接受的盐，其中n，R1，R2，R3，R4，X和Z的定义如本文所述。还提供了含有MIF抑制剂和药学上可接受的载体组合的组合物，以及使用它们的方法。
• Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
  申请人：Sircar Jagadish

  公开号：US20070054922A1

  公开（公告）日：2007-03-08

  Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 3 , R 4 , X, and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了MIF抑制剂，对治疗多种疾病具有用处，包括治疗与MIF活性相关的病理性状况。MIF抑制剂具有以下结构，包括立体异构体、前药和其药学上可接受的盐，其中n、R1、R2、R3、R4、X和Z的定义如本文所述。还提供了含有MIF抑制剂和药学上可接受的载体组合的组合物，以及使用它们的方法。
• AZO-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS
  申请人：Kwong Cecil D.

  公开号：US20110286964A1

  公开（公告）日：2011-11-24

  The present invention provides compounds of Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R 1 , X, Y, Z, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 18 , R 19 , and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing dieases or disorders such as viral infections and virus-related disorders.

  本发明提供了式(I)的化合物：（将在论文中以纸质形式出现的化学式插入此处）（I）及其互变异构体、异构体和酯类，以及所述化合物的药学上可接受的盐、溶剂化物和前药，其中每个R、R1、X、Y、Z、R2、R3、R4、R5、R6、R7、R8、R9、R18、R19和n均是独立选择并如所定义。还提供了包含此类化合物的组合物。本发明的化合物是HCV抑制剂，可用于治疗或预防病毒感染和与病毒相关的疾病或障碍，单独或与其他治疗剂一起使用。
• Tubulysin analogs and methods for their preparation
  申请人：PFIZER INC.

  公开号：US10723727B2

  公开（公告）日：2020-07-28

  The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.

  本发明涉及新型细胞毒性管胞素类似物和衍生物、其抗体药物共轭物以及用其治疗包括癌症在内的病症的方法。